Microglia, the brain's resident immune cells, have long been cast as accelerators of Alzheimer's disease because they drive inflammation. A new study from Trinity College Dublin, published in the neurology journal Brain, complicates that picture: when researchers reduced the number and activity of microglia in a widely used mouse model of Alzheimer's, abnormal electrical activity in the brain got worse and seizure-like events became more frequent.
The work, carried out by teams from Trinity's School of Biochemistry and Immunology and its School of Medicine, points to microglia as guardians of network stability rather than simply agents of damage. That distinction matters because Alzheimer's is not only a disease of memory loss. Scientists increasingly recognize that it disrupts the brain's electrical rhythms and interferes with how populations of neurons communicate, and those disturbances can include silent or overt seizure activity.
The practical implication is a caution against drug strategies that broadly shut microglia down. If these cells are helping keep neuronal circuits from tipping into hyperexcitability, indiscriminate suppression could backfire, trading a reduction in inflammation for more electrical instability. The finding argues instead for approaches that target specific harmful microglial functions while leaving their protective ones intact.
Alzheimer's affects more than 55 million people worldwide and remains the leading cause of dementia, so the question of how to modulate brain immunity without doing collateral harm is a consequential one. These results come from a mouse model, and the next step will be determining how closely the same microglial balancing act operates in the human brain.